Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Prof. Joachim Spatz is a Full Professor of Biophysical Chemistry at Heidelberg University and Director of the Max Planck Institute for Medical Research. His academic career includes roles as Director at MPI for Metals Research (2004–2015) and Founding Director of the Institute for Molecular Systems Engineering (IMSE). He holds a PhD from Ulm University and habilitation in Physics, with postdoctoral training at the Institut Curie, Paris. His research spans cellular biophysics, materials science, and synthetic biology, focusing on mechanotransduction, cell-material interactions, and engineered biological systems. Education: 1989–1994: Dipl. Phys. (Physics), Ulm University & Colorado State University 1994–1996: PhD (summa cum laude), Ulm University 2000: Habilitation in Physics, Ulm University Research Interests: Spatz’s work integrates biophysics, materials science, and engineering to study cellular mechanics, synthetic cells, and mechanosensing. Key projects include developing synthetic cell models using microfluidics and exploring how mechanical forces regulate cell behavior in health and disease. Awards: 2017 Gottfried Wilhelm Leibniz Prize 2012 ERC Advanced Grant (with Prof. B. Geiger) 2002 Alfried Krupp Research Award Labs & Collaborations: Leads the Cellular Biophysics Department at MPI for Medical Research and collaborates with institutions like the Weizmann Institute and Jackson Laboratory. Active in interdisciplinary initiatives such as the Max Planck School Matter to Life.
Prof. Andreas Bausch holds the Heinz Nixdorf Endowed Chair of Cell Biophysics at the Technical University of Munich (TUM) within the TUM School of Natural Sciences . His research focuses on cellular biophysics , particularly the mechanical properties of cytoskeletal networks and self-organization mechanisms in biological systems, with applications in biomimetic materials and organoid modeling. Research Areas : Cytoskeletal mechanics, active matter systems, organoid morphogenesis, integrin signaling, synthetic cell models Techniques : Microrheology, in vitro reconstitution, microfluidics, advanced imaging His work has produced over 100 publications in Nature, Science, PNAS , and Physical Review Letters , with recent emphasis on pancreatic cancer organoids and artificial cell membranes . Key findings include: Discovery of topological excitations governing endothelial cell ordering Elucidation of PIP2/PIP3 regulation in integrin phase separation Development of 3D patterned organoid systems for drug screening Major awards include: ERC Synergy Grant (2018) ERC Advanced Grant (2012) ERC Starting Grant (2011) Berlin-Brandenburg Academy of Sciences Prize (2014) He serves as founding director of the Center for Functional Protein Assemblies (CPA) since 2015 and teaches biomechanics , biophysics , and protein assemblies at TUM. His lab investigates both fundamental biophysical principles and their medical applications in cancer and cardiovascular systems.
Dr. Timur Alexander Yorgan is a prominent researcher at the Department of Osteology and Biomechanics at University Medical Center Hamburg-Eppendorf (UKE). Holding a Dr. rer. nat. degree, he has established himself as a leading figure in bone biology with over 60 publications spanning from 2013 to 2025. His research is deeply integrated with key institutional research areas including the Hamburg Center of Neuroscience and immunology research networks at UKE. Dr. Yorgan's research focuses on skeletal development, bone remodeling, and genetic bone disorders, with particular emphasis on Wnt signaling pathways and their role in bone homeostasis. His work spans multiple approaches from molecular genetics to translational studies, investigating osteoblast and osteocyte biology, genetic mechanisms underlying disorders like osteogenesis imperfecta, and the effects of various mutations on skeletal integrity. Recent research has expanded into the gut-bone axis, mechanobiology of bone cells, and neuro-immune interactions affecting bone metabolism. Analysis of Dr. Yorgan's publication record reveals a consistent trajectory of high-impact research in bone biology. His work increasingly explores interdisciplinary connections between bone metabolism and other physiological systems, with growing emphasis on translational approaches for therapeutic interventions. The research demonstrates sophisticated use of mouse models and molecular techniques to unravel complex bone disorders and identify potential treatment targets. Dr. Yorgan appears to be actively involved in collaborative research across multiple institutions, as evidenced by his extensive publication record with numerous co-authors from various departments and institutions. His work is frequently published in high-impact journals including Journal of Bone and Mineral Research, Nature Communications, and Bone Research. The Department of Osteology and Biomechanics at UKE, where Dr. Yorgan is based, is part of a vibrant research ecosystem that includes the Hamburg Center of Neuroscience and other key research networks focusing on immunology, oncology, and cardiovascular research. This collaborative environment enables interdisciplinary approaches to understanding skeletal disorders and developing novel therapeutic strategies.
Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters
Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.
Prof. Dr. Bart Jan Ravoo is a Professor of Organic Chemistry at the University of Münster, Germany, where he leads the "Synthesis of Nanoscale Systems" research group. He is also co-director of the Center for Soft Nanoscience (SoN) and spokesperson of the Collaborative Research Center (CRC 1459) "Intelligent Matter". His research focuses on creating novel nanoscale materials through supramolecular chemistry and molecular self-assembly. Prof. Ravoo received his PhD from the University of Groningen in 1998 and completed postdoctoral work at University College Dublin. He joined the University of Münster in 2007 as a professor, after serving as an assistant professor at the University of Twente. From 2012-2014, he served as Dean of the Department of Chemistry and Pharmacy. His research spans three main areas: biomimetic supramolecular chemistry, surface functionalization by molecular self-organization, and responsive materials. Prof. Ravoo's group is particularly known for developing photoresponsive materials using arylazopyrazoles and cyclodextrin-based systems for applications ranging from drug delivery to smart adhesives. His work often bridges the gap between fundamental molecular design and practical applications in biomedicine and materials science. Prof. Ravoo's recent publications demonstrate a strong focus on light-responsive materials, with particular emphasis on arylazopyrazole and arylazoisoxazole photoswitches. His research shows how molecular photoswitches can be integrated into various material systems including hydrogels, nanoparticles, and surface coatings to create materials with tunable properties that respond to specific wavelengths of light. This work has important implications for drug delivery, sensing, and adaptive materials. Recipient of the Schering-Plough Newman Scholarship in Organic Chemistry Member of the "Cells in Motion" research cluster Supervisor in the CiM-IMPRS Graduate Programme Prof. Ravoo has supervised over 40 PhD students and has been instrumental in establishing interdisciplinary research collaborations at the University of Münster. His group, consisting of approximately 25 researchers, is supported by multiple funding agencies including the Deutsche Forschungsgemeinschaft (DFG), European Union, and Volkswagen Foundation.
Prof. Dr. Leonid Ionov is a leading academic at the Faculty of Engineering Science , University of Bayreuth, specializing in Biofabrication and 4D Printing . He has held professorial roles since 2017, with prior positions at the University of Georgia and TU Dresden. Research Priorities: Smart responsive polymers, 3D/4D bioprinting, self-healing electronics, and bioinspired surface engineering. Teaching: Offers advanced courses in 3D Printing of Polymers , Biofabrication , and Polymer Science . His work integrates stimuli-responsive materials with additive manufacturing to create bioinspired actuators, vascular scaffolds, and self-healing conductive systems. Recent articles focus on 4D-printed vascular junctions , multi-responsive cellulose composites , and dynamic bilayer morphing . Scientific Achievements Recipient of the 2022 North Bavaria Business Plan Competition award 2012 Georg Manecke Prize for biopolymer research Developed European patents for Li-S battery cathodes and microfluidic devices Trained over 20 PhD/postdoc alumni now at institutions like Iowa State University and Harvard Medical School . Leads a multidisciplinary lab with advanced equipment for polymer synthesis, electrospinning, and cell culture studies.
Prof. Dr. Georg Garnweitner is a full Professor of Nanomaterials at the Institute for Particle Technology , Faculty of Mechanical Engineering, Technische Universität Braunschweig. He has served as Dean of Studies since 2023, DFG Liaison Lecturer since 2021, and head of the Laboratory for Emerging Nanometrology (LENA) board since 2013. University Professorship in Nanomaterials (2013–present) Junior Professorship in Nanoparticles/Nanocomposites (2007–2013) Research at Max Planck Institute (2005–2006) His research focuses on nanomaterial synthesis , non-aqueous nanoparticle formation , and energy storage materials , particularly for lithium-sulfur batteries. He also explores drug delivery systems using silica aerogels and optofluidic particle analysis . His work combines materials science , surface chemistry , and advanced characterization techniques . Recent publications highlight breakthroughs in solid-state electrolyte design (2023), solvent-free drug loading (2022), and nanoparticle migration dynamics (2020). He contributes to crystal engineering (2021) and population balance modeling (2017) for nanoparticle formation.
Christian Becker is an Associate Professor in the Department of Dermatology at the University of Münster, where he leads the Becker Research Group focused on "Adaptive and innate T cell Immunity." His work bridges immunology, dermatology, and vascular biology, with particular emphasis on understanding T cell responses in inflammatory conditions and thrombosis. Dr. Becker's research interests include: T cell function and differentiation Myeloid cell differentiation Nanoparticle-mediated tumor therapy Humanized mouse models Regulatory T cells in tissue repair Monocytes in chronic venous insufficiency His recent work has explored how cyclic adenosine monophosphate (cAMP) serves as a signaling messenger in immune regulation, how specialized regulatory T cells control venous blood clot resolution through SPARC, and how nanoparticle-based therapies can be used for melanoma treatment. His research combines molecular immunology with translational approaches to develop novel therapeutic strategies for inflammatory and thrombotic conditions. Dr. Becker has published extensively in high-impact journals including Nature Communications, Blood, and Circulation Research. His publication record demonstrates a consistent focus on the intersection of immunology and vascular biology, particularly examining how T cells and monocytes interact in thrombotic and inflammatory conditions across multiple disease contexts. His laboratory recently relocated from Mainz to Münster, where he continues to expand his research program. Dr. Becker actively mentors doctoral student Doğa Uncuer and master's student Friederike Pauline Neesen, and is seeking additional talented scientists to join his team.
Prof. Barbara Wohlmuth is a full professor in Numerical Mathematics at the Technical University of Munich (TUM), affiliated with the TUM School of Computation, Information and Technology. She leads the International Graduate School of Science and Engineering at TUM and has held professorships at Stuttgart, Darmstadt, and Berlin universities. Her research focuses on numerical simulation of partial differential equations, multiscale solvers, and coupled multi-field problems with applications in engineering. Education: Studied mathematics at TUM and Université Joseph Fourier in Grenoble, received her doctorate from TUM in 1995, and completed habilitation in Augsburg. Visiting professorships in USA, France, and Hong Kong. Research interests include discretization techniques, predictive modeling, and interdisciplinary collaboration with engineering disciplines. Notable achievements: 2012 Gottfried Wilhelm Leibniz Prize (Germany’s highest academic honor in sciences), 2005 Sacchi-Landriani Prize. Publications emphasize advanced numerical methods in fluid dynamics, geophysics, and biomedical engineering. Active in editorial roles for international journals and scientific committees across Europe and USA. Elected member of Bavarian and European Academies of Sciences. Key contributions include: Development of robust numerical algorithms for exascale simulations Pioneering work in coupled multi-physics modeling Innovative methods for computational contact mechanics Leadership in graduate education initiatives
Sonja Schelhaas is a researcher affiliated with the European Institute for Molecular Imaging (EIMI) at the University of Münster. Her work focuses on molecular imaging technologies, particularly in oncology and neurological contexts. PhD in Medical Biochemistry (2007-2010) Postdoc at EIMI since 2010 Research Fellow in Anaesthesiology (2005-2006) Her research spans: PET tracer development for ion channels Molecular imaging of tumor microenvironments Applications of small animal PET in disease models Bacterial and inflammatory imaging Radiochemistry and multimodal imaging techniques Epigenetic regulation in cancer Recent publications highlight her contributions to: P2X4 receptor antagonists for PET tracers KCa31 channel imaging in cancer Bacterial detection via radiolabeled compounds FLT PET for tumor proliferation analysis Neurogenesis and blood-brain barrier studies PEGylated nanoparticle characterization Schelhaas has collaborated extensively in preclinical imaging projects, contributing to cancer research, infection monitoring, and neurodegenerative disease modeling. Her work appears in journals like Journal of Medical Chemistry , Cancer Research , and Molecular Imaging and Biology .
Carsten Hopf is a Professor of Bioanalytics and Drug Discovery at Mannheim University of Applied Sciences, leading the Institute of Instrumental Analytics and Bioanalytics and the CeMOS (Center for Mass Spectrometry and Optical Spectroscopy). His work focuses on developing spatially resolved omics technologies (e.g., MALDI-MS imaging) for neurodegenerative and oncological research. He explores lipidomics, proteomics, and metabolomics to understand Alzheimer's disease, glioblastoma, and other neurodegenerative disorders. Key projects include the SMART-CARE-2 BMBF initiative (2023–2026) and DFG-funded research on spatial multi-omics in glioblastoma (SFB 1389). Research interests center on mass spectrometry innovations, including matrix optimization, AI-driven data analysis, and multimodal imaging (e.g., infrared microscopy integration). His lab develops label-free cell assays for drug discovery and studies molecular mechanisms of neurodegeneration. Collaborations span academia and industry, with projects like the M 2 Aind partnership addressing 3D cell culture toxicity assessments. Grants include BMBF, DFG, and EU funding for systems medicine, organoid analysis, and mass spectrometry cores. His technological advancements aim to improve biomarker discovery and translational medicine in neuro-oncology and neurodegeneration.
